Recursion Pharmaceuticals (RXRX) Short-term Investments (2020 - 2026)

Recursion Pharmaceuticals has reported Short-term Investments for 7 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 79.22% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 79.22% YoY), and the FY2025 full-year result was $4.6 million, up 50.87% from the prior year.
• Short-term Investments for Q1 2026 stood at $5.5 million, up from $4.6 million in the prior quarter.
• The five-year high for Short-term Investments was $5.5 million in Q1 2026, with the low at $1.3 million in Q4 2022.
• Historically, Short-term Investments has averaged $2.7 million across 5 years, with a median of $3.0 million in 2024.
• Annual changes were most pronounced in 2022 — Short-term Investments slumped 98.87% — and 2023, when it surged 152.42%.
• Recursion Pharmaceuticals' Short-term Investments stood at $1.3 million in 2022, then jumped by 152.42% to $3.2 million in 2023, then slipped by 5.76% to $3.0 million in 2024, then surged by 50.87% to $4.6 million in 2025, then advanced by 19.96% to $5.5 million in 2026.
• The last three Short-term Investments figures came in at $5.5 million (Q1 2026), $4.6 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.